Skip to main content

Advertisement

SpringerLink
Log in

Current therapies for neuromuscular manifestations of paraneoplastic syndromes

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

The neuromuscular manifestations of paraneoplastic disorders result in diverse syndromes that may also occur in patients without cancer. In general, treatment of these disorders is the same whether or not there is an underlying malignancy. However, when the disorder is believed to be paraneoplastic, the main concern should be prompt detection and treatment of the tumor, as this has been shown to offer the best chance for neurologic stabilization or improvement. The paraneoplastic neuromuscular disorders can be divided into two main categories: those that are directly mediated by antibodies and those that are believed to result from other immune-mediated mechanisms, including cytotoxic T-cell responses with or without association with specific antibodies. For disorders in which the antibodies are pathogenic, therapy is aimed at removing the antibodies. For the other disorders, adjuvant therapies are for the most part empiric and include a variety of immunosuppressant and immunomodulatory agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Antoine JC, Honnorat J, Camdessanche JP, et al.: Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001, 49:214–221.

    Article  PubMed  CAS  Google Scholar 

  2. Molinuevo JL, Graus F, Serrano C, et al.: Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998, 44:976–980.

    Article  PubMed  CAS  Google Scholar 

  3. Younes-Mhenni S, Janier MF, Cinotti L, et al.: FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004, 127:2331–2338.

    Article  PubMed  CAS  Google Scholar 

  4. Graus F, Keime-Guibert F, Rene R, et al.: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138–1148.

    Article  PubMed  CAS  Google Scholar 

  5. Candler PM, Hart PE, Barnett M, et al.: A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004, 75:1411–1415. In this population-based study of 63 patients with paraneoplastic neurologic disorders, only treatment of the tumor was associated with stabilization or improved neurologic outcome.

    Article  PubMed  CAS  Google Scholar 

  6. Antoine JC, Mosnier JF, Absi L, et al.: Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999, 67:7–14.

    PubMed  CAS  Google Scholar 

  7. Dalmau J, Graus F, Rosenblum MK, et al.: Anti-Huassociated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992, 71:59–72.

    Article  PubMed  CAS  Google Scholar 

  8. Keime-Guibert F, Graus F, Fleury A, et al.: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479–482. In this study of 17 patients, the authors conclude that in patients with sensory neuronopathy associated with Hu antibodies, treatment early in the course offers the best chance for stabilization.

    Article  PubMed  CAS  Google Scholar 

  9. Mowzoon N, Bradley WG: Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: a case report. J Neurol Sci 2000, 178:63–65.

    Article  PubMed  CAS  Google Scholar 

  10. Oh SJ, Dropcho EJ, Claussen GC: Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997, 20:1576–1582.

    Article  PubMed  CAS  Google Scholar 

  11. Vigliani MC, Magistrello M, Polo P, et al.: Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. J Neurol 2004, 251:321–326.

    Article  PubMed  Google Scholar 

  12. Hughes RA, Raphael JC, Swan AV, et al.:Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2004, CD002063.

  13. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004, 102:177–193.

    Article  PubMed  CAS  Google Scholar 

  14. Rotta FT, Bradley WG: Marked improvement of severe polyneuropathy associated with multifocal osteosclerotic myeloma following surgery, radiation, and chemotherapy. Muscle Nerve 1997, 20:1035–1037.

    Article  PubMed  CAS  Google Scholar 

  15. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al.: Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004, 104:3400–3407.

    Article  PubMed  CAS  Google Scholar 

  16. Silberstein LE, Duggan D, Berkman EM: Therapeutic trial of plasma exchange in osteosclerotic myeloma associated with the POEMS syndrome. J Clin Apher 1985, 2:253–257.

    Article  PubMed  CAS  Google Scholar 

  17. Henze T, Krieger G: Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome. J Neurol 1995, 242:482–483.

    Article  PubMed  CAS  Google Scholar 

  18. Donaghy M, Hall P, Gawler J, et al.: Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci 1989, 89:253–267.

    Article  PubMed  CAS  Google Scholar 

  19. Ku A, Lachmann E, Tunkel R, et al.: Severe polyneuropathy: initial manifestation of Castleman’s disease associated with POEMS syndrome. Arch Phys Med Rehabil 1995, 76:692–694.

    Article  PubMed  CAS  Google Scholar 

  20. Fernandez-Torre JL, Polo JM, Calleja J, et al.: Castleman’s disease associated with chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological follow-up study. Clin Neurophysiol 1999, 110:1133–1138.

    Article  PubMed  CAS  Google Scholar 

  21. Bowne WB, Lewis JJ, Filippa DA, et al.: The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999, 85:706–717.

    Article  PubMed  CAS  Google Scholar 

  22. Wilson HC, Lunn MP, Schey S, et al.: Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999, 66:575–580.

    PubMed  CAS  Google Scholar 

  23. Weide R, Heymanns J, Koppler H: The polyneuropathy associated with Waldenstrom’s macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 2000, 109:838–841.

    Article  PubMed  CAS  Google Scholar 

  24. Rudnicki SA, Harik SI, Dhodapkar M, et al.: Nervous system dysfunction in Waldenstrom’s macroglobulinemia: response to treatment. Neurology 1998, 51:1210–1213.

    PubMed  CAS  Google Scholar 

  25. Kyle RA, Rajkumar SV, Therneau TM, et al.: Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma 2005, 5:257–260.

    PubMed  Google Scholar 

  26. Montoto S, Rozman M, Rosinol L, et al.: Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003, 30:178–181.

    Article  PubMed  CAS  Google Scholar 

  27. Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325:1482–1486.

    Article  PubMed  CAS  Google Scholar 

  28. Lee YC, Came N, Schwarer A, et al.: Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance. Bone Marrow Transplant 2002, 30:53–56.

    Article  PubMed  CAS  Google Scholar 

  29. Katz JS, Saperstein DS, Gronseth G, et al.: Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615–620.

    PubMed  CAS  Google Scholar 

  30. Goldfarb AR, Weimer LH, Brannagan TH III: Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle Nerve 2005, 31:510–515.

    Article  PubMed  Google Scholar 

  31. Broglio L, Lauria G: Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 2005, 32:378–379.

    Article  PubMed  Google Scholar 

  32. Comi G, Roveri L, Swan A, et al.: A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002, 249:1370–1377.

    Article  PubMed  CAS  Google Scholar 

  33. Mariette X, Chastang C, Clavelou P, et al.: A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997, 63:28–34.

    Article  PubMed  CAS  Google Scholar 

  34. Hawke SH, Davies L, Pamphlett R, et al.: Vasculitis neuropathy. A clinical and pathological study. Brain 1991, 114:2175–2190.

    Article  PubMed  Google Scholar 

  35. Said G: Necrotizing peripheral nerve vasculitis. Neurol Clin 1997, 15:835–848.

    Article  PubMed  CAS  Google Scholar 

  36. Shillito P, Molenaar PC, Vincent A, et al.: Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995, 38:714–722.

    Article  PubMed  CAS  Google Scholar 

  37. van den Berg JS, Van Engelen BG, Boerman RH, et al.: Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 1999, 246:623–625.

    Article  PubMed  Google Scholar 

  38. Martinelli P, Patuelli A, Minardi C, et al.: Neuromyotonia, peripheral neuropathy and myasthenia gravis. Muscle Nerve 1996, 19:505–510.

    Article  PubMed  CAS  Google Scholar 

  39. De Camilli P, Thomas A, Cofiell R, et al.: The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993, 178:2219–2223.

    Article  PubMed  Google Scholar 

  40. Lorish TR, Thorsteinsson G, Howard FM: Stiff-man syndrome updated. Mayo Clin Proc 1989, 64:629–636.

    PubMed  CAS  Google Scholar 

  41. Vermeij FH, van Doorn PA, Busch HF: Improvement of stiffman syndrome with vigabatrin. Lancet 1996, 348:612.

    Article  PubMed  CAS  Google Scholar 

  42. Murinson BB, Rizzo M: Improvement of stiff-person syndrome with tiagabine. Neurology 2001, 57:366.

    PubMed  CAS  Google Scholar 

  43. Silbert PL, Matsumoto JY, McManis PG, et al.: Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 1995, 45:1893–1897.

    PubMed  CAS  Google Scholar 

  44. Dalakas MC, Fujii M, Li M, et al.: High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001, 345:1870–1876. The first controlled study in non-paraneoplastic stiff-man syndrome demonstrating effectiveness of IVIg.

    Article  PubMed  CAS  Google Scholar 

  45. Baker MR, Das M, Isaacs J, et al.: Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005, 76:999–1001.

    Article  PubMed  CAS  Google Scholar 

  46. Rosin L, DeCamilli P, Butler M, et al.: Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology 1998, 50:94–98.

    Article  PubMed  CAS  Google Scholar 

  47. Folli F, Solimena M, Cofiell R, et al.: Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993, 328:546–551.

    Article  PubMed  CAS  Google Scholar 

  48. Mastaglia FL, Phillips BA, Zilko PJ: Inflammatory myopathy. Curr Treat Options Neurol 1999, 1:263–272.

    Article  PubMed  Google Scholar 

  49. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  50. Hengstman GJ, van den Hoogen FH, Van Engelen BG: Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004, 52:61–63.

    Article  PubMed  CAS  Google Scholar 

  51. Miller FW, Leitman SF, Cronin ME, et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380–1384.

    Article  PubMed  CAS  Google Scholar 

  52. Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999, 52:1701–1704.

    PubMed  CAS  Google Scholar 

  53. Vasconcelos OM, Dalakas MC: Stiff-person syndrome. Curr Treat Options Neurol 2003, 5:79–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Section of Neuro-Oncology, 3 West Gates, University of Pennsylvania, 3400 Spruce Street, 19104, Philadelphia, PA, USA

    Josep Dalmau MD, PhD

Authors
  1. Myrna R. Rosenfeld MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josep Dalmau MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Dalmau MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenfeld, M.R., Dalmau, J. Current therapies for neuromuscular manifestations of paraneoplastic syndromes. Curr Neurol Neurosci Rep 6, 77–84 (2006). https://doi.org/10.1007/s11910-996-0012-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-996-0012-0

Keywords

Search

Navigation